Navigation Links
Study details cost-effectiveness of rheumatoid arthritis treatments for Medicare recipients
Date:4/14/2008

For elderly and disabled rheumatoid arthritis (RA) sufferers, the Medicare Prescription Drug Improvement and Modernization Act (MMA) brought the promise of better disease management with biologic drugs. Prior to its passage in 2006, Medicare covered only one of the tumor necrosis factor (TNF) inhibitors, the infusion drug infliximab, also known by its brand name, Remicade. Since the MMA, most Medicare prescription drug plans offer coverage of the anti-TNF self-injectables etanercept (Enbrel) and adalimumab (Humira), as well as the interleukin-1 receptor antagonist anakinra (Kineret). More effective at controlling the painful and crippling symptoms of RA than conventional disease-modifying antirheumatic drugs (DMARDs), biologic drugs are also more expensive. According to a recent study, this new class of therapies has increased the cost of treating a patient with RA in the United States 3-fold.

To help Medicare beneficiaries and their providers select the best-value treatment option, a team of researchers, supported by the Agency for Healthcare Research and Quality of the U.S. Department of Health and Human Services, developed a mathematical model to estimate the costs and benefits of etanercept, adalimumab, and anakinra compared with those of infliximab over a patients lifetime. Their results, featured in the April 2008 issue of Arthritis & Rheumatism ( www.interscience.wiley.com/journal/arthritis ), make a case for coverage of either etanercept or adalimumab over infliximab. In terms of effectiveness, the 3 TNF inhibitors are nearly equal. Getting the same results with infliximab, however, requires paying moreroughly $13,000 moreper patient. Anakinra is substantially less costly than the anti-TNF drugs but also less effective.

The researchers drew on data on RA patients from randomized controlled trials and a storehouse of self-reported patient information, the National Data Bank for Rheumatic Diseases. Starting with baseline characteristicsincluding disease duration and score on the disability index of the Health Assessment Questionnaire (HAQ DI)of actual patients treated with each of the targeted biologic drugs, the model simulated a representative sample of 10,000 RA patients. Using these simulated patients, the model assessed the effectiveness of the 4 options, based on the level of American College of Rheumatology (ACR) response and the HAQ DI score for each patient. Beginning after a 6-month course of biology therapy, scores were taken every 6 months until withdrawal, due, for example, to loss of effectiveness or adverse event, and then, assuming a return to DMARD-based therapy, every 6 months throughout the remainder of the patients life. The score for each patient was translated into quality-adjusted life years (QALYs), a measure of benefit that can be used across a wide range of diseases and treatments. The model then calculated the costs incurred for each Medicare patient, including the costs of the biologic drugs, physician visits, other medications, hospitalizations, radiographs, and laboratory work. Finally, the researchers compared the costs and QALYs generated by each of the 4 biologic agents.

In all simulations, anakinra was found to generate less QALYs than the TNF inhibitors. Excluding anakinra to compare the costs of the 3 almost equally effective drug strategies, researchers used a range of $0 to $200,000 as the values a decision-maker may be willing to pay per additional QALY gained. Infliximab was the optimal strategy in only a handful of the simulations. If society were willing to pay as much as $50,000 per QALY, the probability that infliximab would be cost-effective is less than 1 percent.

Our analysis suggests that the use of etanercept or adalimumab in place of infliximab as a first-line biologic agent is likely to be considered cost effective, concludes the studys lead author, Dr. Allan J. Wailoo. Yet, as he acknowledges, this cost-effective analysis does have several limitations. For one, it does not consider whether any biologic agent is cost-effective compared with traditional DMARD therapy. For another, it focuses only on patients with established disease, averaging 7 or more years in duration. Whats more, only very slight changes in the doses of etanercept and adalimumab were documented in the sample of RA patients on which the simulations were based. Increases in doses will substantially influence the cost and cost-effectiveness of biologic drugs, Dr. Wailoo notes, and it is therefore recommended that this issue be monitored.


'/>"/>

Contact: Sean Wagner
swagner@bos.blackwellpublishing.com
781-388-8550
Wiley-Blackwell
Source:Eurekalert

Related medicine news :

1. Study sheds light on deadly lung disease
2. NovoCure presents results from breast cancer pilot study
3. Mayo-led study finds smoking related to subset of colorectal cancers
4. National hospice study reveals gaps in service
5. Study Points to New Treatments for Polycystic Kidney Disease
6. MRI better than MDCT in detecting endoleaks, study says
7. Personality study shows risk of first depression episode late in life
8. 3T MRI plays significant role in detecting prostate cancer, study says
9. Study shows doctors offices can help stem abuse of Oxycontin, other narcotic painkillers
10. Quintiles Ranks First in Pan-European Clinical Investigator Study
11. Study Showed Minimally Invasive Surgery Reduced Risk of Hospital-Acquired Infections Compared to Open Surgery
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... June 25, 2016 , ... As a lifelong Southern Californian, Dr. ... his M.D from the David Geffen School of Medicine at UCLA. He trained in ... to complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he ...
(Date:6/25/2016)... ... June 25, 2016 , ... On Friday, June 10, ... Bronze Wellness at Work award to iHire in recognition of their exemplary accomplishments in ... the 7th annual Maryland Workplace Health & Wellness Symposium at the BWI Marriott in ...
(Date:6/24/2016)... CA (PRWEB) , ... June 24, 2016 , ... A ... procedures that most people are unfamiliar with. The article goes on to state that ... but also many of these less common operations such as calf and cheek reduction. ...
(Date:6/24/2016)... Marne, Michigan (PRWEB) , ... June 24, 2016 , ... ... awareness about the dangers associated with chronic pain and the benefits of holistic treatments, ... for individuals who are suffering with Sickle Cell Disease. , Sickle Cell Disease (SCD) ...
(Date:6/24/2016)... ... June 24, 2016 , ... The Pulmonary Hypertension Association ... it will receive two significant new grants to support its work to advance ... 25th anniversary by recognizing patients, medical professionals and scientists for their work in ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)...  MedSource announced today that it has selected ... of choice.  This latest decision demonstrates MedSource,s commitment ... clients by offering a state-of-the-art electronic data capture ... as the EDC platform of choice in exchange ... has long been a preferred EDC platform by ...
(Date:6/23/2016)... ITASCA, Ill. , June 23, 2016  In a startling ... states are failing their residents by lacking a comprehensive, proven plan ... , a definitive ranking of how states are tackling the ... rating to only four states – Kentucky , ... and Vermont . Of the 28 failing states, ...
(Date:6/23/2016)... , June 23, 2016 Research and ... News Issue 52" report to their offering. ... influenza treatment creates a favourable commercial environment for MedImmune to ... patient base that will serve to drive considerable growth for ... would serve to cap sales considerably, but development is still ...
Breaking Medicine Technology: